COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI HC QHC Q BHBH CICI BLBL NZNZ COCO BUBU More..
Proxalutamide study #1 of 3
12/30 Early treatment study
Cadegiani et al., Research Square, doi:10.21203/rs.3.rs-135303/v1 (Preprint)
Proxalutamide (GT0918) Reduces the Rate of Hospitalization and Death in COVID-19 Male Patients: A Randomized Double-Blinded Placebo-Controlled Trial
Source   PDF   Share   Tweet
RCT 214 male patients in Brazil, 114 treated with proxalutamide, showing significantly lower hospitalization and mechanical ventilation. NCT04446429.

Cadegiani et al., 12/30/2020, Double Blind Randomized Controlled Trial, Brazil, South America, preprint, 7 authors.
risk of death, 81.1% lower, RR 0.19, p = 0.22, treatment 0 of 114 (0.0%), control 2 of 100 (2.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of mechanical ventilation, 95.1% lower, RR 0.05, p < 0.001, treatment 0 of 114 (0.0%), control 9 of 100 (9.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of hospitalization, 98.3% lower, RR 0.02, p < 0.001, treatment 0 of 114 (0.0%), control 27 of 100 (27.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 3 studies
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation.
Submit